Author: michael987

Over time, important advances in diagnosis and the development of versatile treatment options have translated into tangible improvements in the overall survival of lung cancer patients; several targeted therapies are... Read More

Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications London Roots Analysis has announced the addition of “Vascular Disrupting Agents Market,... Read More

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments in this industry Roots Analysis has announced... Read More

A major increase in the number of different types of solutions for treating various indications, has been observed in the past two years. In fact, from June 2018 to in... Read More

The primary purpose of this analysis was to develop a deeper understanding of the overall strength of the contract service providers involved in this field. It allows companies to compare... Read More

Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and... Read More

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players... Read More

The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the... Read More

Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing Roots Analysis is... Read More